Fritextsökning
Artiklar per år
Innehållstyper
-
Fetmaläkemedel från Novo Nordisk prövas mot hjärt- kärlhändelser
Det danska läkemedelsbolaget Novo Nordisk genomför för närvarande Select-studien där bolaget undersöker om huruvida bolagets fetmaläkemedel Wegovy kan minska risken för hjärt- kärlhändelser.
-
We will now publish more news in English – and offer yet another newsletter
Starting next week, Life Science Sweden will begin offering a newsletter entirely in English.
-
Rapport: ESS ekonomiskt positivt för Sverige
2021 fick två professorer i uppdrag att analysera de samhällsekonomiska effekterna av bygget av forskningsanläggningen ESS i Lund. Rapporten visar att svenska företag har stått sig väl i konkurrensen om ordrar från ESS.
-
When carelessness, forgetfulness and coincidence become the researcher’s best friend
Forgetfulness, coincidence and a stroke of luck hardly make up a fruitful method of serious research. Or do they? Actually, a number of important medical advances have come about thanks to completely random incidents and the open-mindedness of scientists
-
Søren Bregenholt omvald som ordförande i MVA
Under Medicon Valley Alliance årsstämma fick styrelsen förnyat förtroende och valdes om.
-
Lucy Robertshaw: Are we in the perfect storm?
“Is there a perfect storm on the horizon again as elective surgeries were cancelled due to patients being admitted with Covid-19? We now have a long backlog of people who are presenting with chronic diseases that need to access healthcare again”, writes
-
80 anställda berörs när Sobi slutar tillverka läkemedel åt Pfizer
Sobi slutar tillverka läkemedelssubstansen Refacto i förtid sedan avtalet med Pfizer ändrats. Ett 80-tal anställda påverkas, enligt företaget.
-
Key2compliance expanderar till Danmark
För första gången etablerar sig medicinteknik- och läkemedelskonsulterna Key2compliance utanför Sveriges gränser.
-
This is how Anette Steenberg will put Medicon Valley on the world map
Anette Steenberg has been CEO of the Swedish-Danish life science cluster Medicon Valley Alliance since 1 November last year. Life Science Sweden called her to ask about her visions and the challenges of merging the worlds of Swedish and Danish life science.
-
Björn Ursing: Physicians new role in AI driven healthcare
”AI could be the key we need for tomorrow’s healthcare, but it is not a stand-alone tool”, writes Björn Ursing in a column about how the role for physicians changes in the era of AI.
-
Elicera develops CAR-T against solid tumours – may become the first in the world
Today, there are five EU-approved CAR-T therapies, all focused on different types of blood cancer, but no one has yet succeeded in making the method work against solid tumours. At Gothenburg-based Elicera, they are working relentlessly to succeed in that field as well. “It is the largest field, and the potential is enormous,” says the company’s CEO Jamal El-Mosleh.
-
CAR-T therapies give continued hope: “Almost half of the patients have become disease-free”
When the first CAR-T therapies appeared, hopes were raised for the effective treatment for critically ill cancer patients. After a somewhat sluggish start, about 90 patients in Sweden have now been treated with this method. “Almost half of them have
-
Stor enkät: Så agerar universiteten på Putins krig mot Ukraina
Svenska lärosäten avslutar nu samarbeten med ryska och belarusiska statliga institutioner. Life Science Sweden har talat med samtliga svenska universitet med medicinska fakulteter. "Forskning är i sin natur internationell, men det är ingen tvekan om att här går stödet för de demokratiska principerna före”, är en av kommentarerna.
-
Samuel Lagercrantz: Immunotherapy against cancer is still in its early stages
For more than 100 years, researchers have tried to target the body’s own immune system to fight cancer cells. They have occasionally been laughed at and ridiculed by the medical establishment. However, from our perspective today, we can sum it up with the saying: He who laughs last laughs best, writes Samuel Lagercrantz in an editorial.
-
Björn Arvidsson: ”We need to change perspective”
If you say “life science” to a person on the street and ask them to explain what it is, you will probably get no good answer. The same question to your network will generate as many versions as the people you ask. Most likely, we will miss many opportunities with our lack of communication, writes Björn Arvidsson in a column.
-
A new international stem cell research centre has been created in Copenhagen
A new centre for stem cell research opened to the public in January. The Novo Nordisk Foundation backs the initiative with the ambition that the centre will advance new medical technology and new stem cell therapies.
-
Marie Gårdmark: Finally, it’s time for a revision of the EU pharma legislation
A challenge for the EU Commission is to deliver a new framework that will also take care of another “pillar” of the pharmaceutical strategy, namely, to ensure that new medicines will be available for all citizens in Europe, writes Marie Gårdmark
-
BMS stämmer svenskt forskningsbolag för patentintrång
Den globala läkemedelsjätten Bristol-Myers Squibb (BMS) stämmer det svenska forskningsbolaget Xspray Pharma för patentintrång kopplat till läkemedelskandidaten Dasynoc.
-
Lundbeck behind the first EU-approved intravenous migraine treatment
A preventive, intravenous treatment for migraines has been approved in the EU for the first time.
-
Life Science Sweden´s international issue is on its way
A new issue of Life Science Sweden is on its way to print, packed with news, interviews and reports.
-
Study: An objective diagnosis of constant tinnitus may be possible
A new method that measures brain activity during sound stimulation can make it possible to objectively diagnose and identify people who suffer from constant tinnitus, which was demonstrated in a study made by researchers at the Karolinska Institute.
-
Pfizers medicinske chef: ”Hela andan på företaget är oerhört patientfokuserad”
Som anestesiläkare i Lund hjälpte Jonas Ålebring en patient i taget. Som Pfizers nye medicinske chef har han möjligheten att hjälpa tusentals patienter samtidigt – det och företagets patientfokus är anledningar till att han valde att hoppa på jobbet i höstas.
-
Patient som fick grishjärta återhämtar sig – inga tecken på avstötning
Den amerikanske man som fick ett genmodifierat grishjärta transplanterat i början av året återhämtar sig fortfarande på sjukhus. Efter fem veckor syns inga tecken på avstötning, enligt läkare.
-
“Together Stockholm-Uppsala and Medicon Valley can make Scandinavia a leading life science region”
“Denmark, Sweden, Norway and Finland all have national life science strategies, but the Swedish strategy is the only one explicitly emphasizing the Nordic dimension. But what if the leading life science nations, Denmark and Sweden, joined forces, took the lead and pioneered Nordic life science collaboration? Wouldn´t we then be able to "bake a bigger cake?", writes Anette Steenberg and Ulf G. Andersson in a debate article.
BREAKING